Background: The incidence of breast cancer in Japanese women has doubled in all age groups over the past two decades.
introduction
Currently, breast cancer is the most common cancer among women in Japan. Its incidence in Japanese women has doubled in all age groups over the past two decades, and the agestandardized incidence rates were estimated at 30.4/100 000 in 1984 and 62.0/100 000 in 2004 (Center for Cancer Control and Information Service, National Cancer Center, Japan http://ganjoho.jp/pro/statistics/en/gdball.html?1%2%1# Graph). Generally, the incidence remains only one-third of that seen in women in North American and European countries (Surveillance Epidemiology and End Results Cancer Statistics, USA, and Cancer Research, UK). However, the age-specific incidence in women <50 years of age is similar to that in the United States and the UK, and the peak age of age-specific incidence in Japanese women is 45 years old [1] .
Parity is strongly associated with breast cancer risk in both premenopausal and postmenopausal women [2] [3] [4] . The Ministry of Health, Labor, and Welfare in Japan reported that the total fertility rate, which is the average number of children that would be born to a woman over her lifetime, has decreased since the 1970s from an estimated 2.16 in 1971 to an estimated 1.32 in 2006; in contrast, the incidence of breast cancer has been increasing.
In addition, it is well known that obesity is associated with an increased risk of breast cancer among postmenopausal women. Interestingly, the average body mass index (BMI) in Japanese women in their 30s to 60s has reduced during the past decade, despite the fact that BMI tends to increase with age, and that in all age groups during the past decade the average height has increased while the average weight has remained unchanged (size-JPN [2004] [2005] [2006] , conducted by the Ministry of Economy, Trade, and Industry of Japan).
Recent gene expression-based molecular classification has revealed that breast cancer is not one disease but a collection of several biologically different diseases [5, 6] . There are large-scale molecular differences between estrogen receptor (ER)-positive and ER-negative breast cancers that reach far beyond the presence or absence of ER. The Breast Cancer Risk Assessment Tool (i.e., the Gail model) is used to predict the risk of breast cancer in Western countries, and the Gail model has identified populations at increased risk of ER-positive breast cancer in postmenopausal women [4, 7] . Moreover, genomewide association studies have identified genetic susceptibility loci for breast cancer by ER status [8] [9] [10] [11] [12] [13] .
To investigate the possible reasons for the recent increased incidence of breast cancer in Japan, we examined the characteristics of the tumors treated between 1982 and 2010, stratified by age group and ER status, as assessed by immunohistochemistry (IHC), and found that the recent notable increase of breast cancer incidence is mostly due an increase in the ER-positive subtype, especially in women aged 50 years or younger. We also analyzed the characteristics and prognosis in ER-positive, HER2-negative breast cancer, which is the most common and increasing subtype, by age group.
patients and methods

patients and breast cancer samples
The study included 1903 consecutive Japanese women with breast cancer, which were newly diagnosed at Nagoya City University Hospital between January 1982 and March 2010. The study protocol was approved by the institutional review boards and conformed with the guidelines of the 1996 Declaration of Helsinki. Stage (tumor-node-metastasis clinical classification) was classified according Union for International Cancer Control, sixth edition, 2002. All patients except for those with stage IV disease underwent surgical treatment (mastectomy or lumpectomy). Tumor samples of patients with stage IV disease were taken by core needle biopsies. Patients received adequate endocrine or chemotherapy for adjuvant or metastatic diseases.
immunohistochemical evaluation of ER, PgR, and HER2 status
The ER, progesterone receptor (PgR), and HER2 status of the breast cancer tissues was assessed by IHC. One 4-lm section of each submitted paraffin block was stained first with hematoxylin-eosin to verify that an adequate number of carcinoma cells were present and that the fixation quality was adequate for IHC analysis. Serial sections (4 lm) were prepared from selected blocks and float-mounted on adhesive-coated glass slides, for staining of the expression of ER, PgR, and HER2 as described previously [14] . Primary antibodies included monoclonal mouse anti-human ERa antibody (1D5, DAKO, Glostrup, Denmark) at 1:100 dilution for ER, and monoclonal mouse anti-human PgR antibody (636, DAKO) at 1:100 dilution for PgR. The DAKO EnVision system (DAKO EnVision labeled polymer, peroxidase) was used as the detection system. Immunostained slides were scored after the entire slide was evaluated by light microscopy. Any brown nuclear staining in breast epithelium was counted as positive cells. The expression of ER and PgR was scored by assigning proportion and intensity scores, according to Allred's procedure [15] . Tumors with ‡1% positive cells (proportion score ‡2) were evaluated as positive [16, 17] .
Immunostaining of HER2 was evaluated using the same method as employed by the HercepTest (DAKO). To determine the HER2 expression score, the membrane staining pattern was estimated and scored on a scale of 0-3+. Scores 0 and 1+ were considered negative, and 3+ was considered positive. Tumors with a sore of 2+ were tested for gene amplification by FISH using the PathVysion assay (Vysis, Abbott Laboratories, Abbott Park, IL). A ratio of HER2 gene/chromosome 17 ‡ 2.0 was considered positive. Tumors were considered HER2 positive if IHC staining was 3+ or FISH positive [18] .
statistical analysis
To compare the hormone receptor and HER2 status among the three time periods (namely, 1982-1991, 1992-2001, and 2002-2010) and two age groups (£50 and >50 years of age), the chi-square test was used. Spearman's rank correlation test was used to study relationships between clinicopathological factors and hormone receptor scores. Estimation of disease-free and overall survival was carried out using the Kaplan-Meier method, and differences between survival curves were assessed with the logrank test. Cox's proportional hazards model was used for univariate and multivariate analyses of prognostic values. results changes in the frequency of breast cancer according to ER and PgR status A total of 1903 Japanese women with breast cancer were treated and analyzed for ER status at the Nagoya City University Hospital between January 1982 and March 2010. We analyzed ER and PgR status by age group during the three study periods (Table 1) . Surprisingly, the frequency of ER-positive breast cancer in women aged 50 years or younger increased greatly over the interval studied 78.6%, P = 0.029), whereas the frequency of PgR-positive tumors was 60% in women over 50 years of age in all three study periods. When combined ER and PgR status was analyzed, during the three study periods, the proportion of ERpositive (+)/PgR-positive (+) tumors greatly increased in women aged 50 years or younger, whereas the proportion of ER-negative (2)/PgR+ and ER2/PgR2 tumors significantly decreased (P < 0.0001). The proportion of ER2/PgR+ and ER2/PgR2 tumors also decreased significantly over time in the >50 years of age group (P = 0.045).
The frequency of noninvasive carcinoma (stage 0) increased significantly during the three study periods (1982-1991: 2.2%, 1992-2001: 3.1%, 2002-2010: 10.9%, P < 0.0001). However, there was no difference between the frequency of noninvasive carcinoma and invasive carcinoma with respect to ER status, and the ratios of ER-positive breast cancer were 78.7% in noninvasive carcinoma and 77.1% in invasive carcinoma.
changes in the frequency of invasive breast cancer according to HER2 status HER2 status in invasive breast cancers was analyzed by age group between 1982 and 2010 ( Table 2 ). The frequency of HER2-positive breast cancer was 10% over the three time periods in both age groups. When the combined ER and HER2 status was analyzed, the frequency of ER+/HER22 tumors increased greatly over the interval studied, especially in women clinicopathological characteristics in ER-positive, HER2-negative breast cancer
We next examined correlations between clinicopathological factors and hormone receptor scores in ER-positive, HER2-negative breast cancer (Table 3 ). Patient's age was positively associated with expression levels of ER (P < 0.0001), and negatively correlated with expression levels of PgR (P < 0.0001).
Tumor grade was negatively correlated with expression levels of ER (P = 0.0029) and PgR (P < 0.0001). ER and PgR Allred expression scores were compared between the two age groups (Figure 1 ). Although most tumors in women 50 years or younger showed high ER expression scores of ‡6, tumors with a score of 8 were found significantly less frequency compared with women over 50 years of age in whom 70% of tumors had an ER expression score of 8 ( Figure 1A ). In contrast, in women aged 50 years or younger, most tumors had high PgR expression scores, especially scores of 7 and 8, whereas the distribution of PgR scores was evenly spread in tumors in women over 50 years of age ( Figure 1B) . adjuvant therapies and prognosis in ER-positive, HER2-negatve breast cancer by age group
We then analyzed the prognosis of patients with ER-positive, HER2-negative breast cancer treated between 1982 and 2006, by age group. Characteristics of patients and tumors are shown in Table 4 . Kaplan-Meier analysis showed that disease-free and overall survival significantly improved over time in both age groups (Figure 2A-D) . Indication and the choice of the drugs of adjuvant endocrine and chemotherapies have changed during the three time periods. Between 2002 and 2006, 57.6% of women aged 50 years or younger received endocrine therapy alone, and 34.3% received both endocrine and chemotherapy, whereas 60.9% of women over 50 years of age received endocrine therapy alone and 20.2% received both endocrine and chemotherapy (Tables 5 and 6 ). In women aged 50 years or younger, 25% of patients did not receive adjuvant endocrine (Table 6 ). In addition, anthracyclines and taxanes have been indicated as standard chemotherapy for high-risk patients since 2002, although oral 5-fluorouracil derivatives were frequently administered for 2 years as adjuvant chemotherapy during 1980s and 1990s (Tables 5 and 6 ). Kaplan-Meier analysis showed that tumor size ( Figure 3A -D) and lymph node status ( Figure 4A-D) were strongly associated with disease-free and overall survival in both age groups. Tumor grade was significantly correlated with diseasefree and overall survival in women aged 50 years or younger ( Figure 5A and B), whereas no association was observed between grade and survival in women over 50 years of age ( Figure 5C and D) . Univariate analysis demonstrated that significant association between disease-free survival and tumor size (P < 0.0001), lymph node status (P < 0.0001) and tumor grade (P = 0.0031) was found in women aged 50 years or younger (Table 7) . However, there was no association between disease-free survival and expression scores of ER and PgR in this younger age group. Multivariate analysis revealed that tumor size (P = 0.0007) and lymph node status (P < 0.0001) were prognostic factors for improved disease-free survival in women aged 50 years or younger. In women over 50 years of age, lymph node status (P < 0.0001) was the only prognostic factor for improved disease-free survival in multivariate analyses, although a significant association was found between disease-free survival and tumor size (P = 0.0006) and lymph node status (P < 0.0001) in univariate analysis.
discussion
In this study, we have shown that the recent notable increase of breast cancer incidence is mostly due an increase in the ERpositive subtype, especially in women aged 50 years or younger. The Japanese Breast Cancer Society reported that, in Japan in 2006, there were 4899 women (81.1%) with ER-positive tumors among 6043 registered breast cancer patients under 50 years of age, and 10 152 women (73.3%) with ER-positive tumors among 13 783 registered breast cancer patients aged ‡50 years (Breast Cancer Statistics in Japan, 2006, conducted by the Japanese Breast Cancer Society). Almost 50% of newly diagnosed breast cancer patients in Japan were registered in this registration system in 2006. Although the incidence rates of ERpositive tumors in Japan seem lower than those in our present study, it may be because of different methods used for the LHRH agonist, luteinizing hormone-releasing hormone agonist for a minimum of 2 years; tamoxifen (TAM) 2 aromatase inhibitors (AI), tamoxifen for 2-3 years followed by aromatase inhibitors for 3-2 years; 5FU, 5-fluorouracil derivatives for 2 years; CMF, cyclophosphamide, methotrexate, and fluorouracil; anthracyclins, AC (doxorubicin and cyclophosphamide), or FEC (fluorouracil, epirubocin, and cyclophosphamide); taxanes, docetaxel, or paclitaxel.
original article Annals of Oncology assessment of ER status. We evaluated tumors with ‡1% positive cells as positive for ER or PgR [16] , whereas in 2006 most hospitals in Japan assessed tumors with ‡10% positive cells as positive for ER or PgR.
Not only the incidence rates but also the frequencies of molecular subtypes of breast cancer differ greatly among ethnic groups [19, 20] . Genome-wide association studies have identified genetic susceptibility loci, such as fibroblast growth factor receptor 2 for breast cancer by ER status [8] . We have previously identified that genetic polymorphisms of ER (ERa), CYP19A1, COMT and p53 genes frequently occur in ERpositive premenopausal breast cancer patients compared with those in patients with ER-negative tumors [21] . It is necessary to establish genetic factors for predicting the risk of ER-positive breast cancer.
In addition to genetic factors, it has been suggested that a change in environmental factors might also be having a notable effect on the increase of breast cancer incidence. Iwasaki and et al. [3] from the Japan Public Health 
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Center-Based Prospective Study reported that early age at menarche for premenopausal women, late age at natural menopause for postmenopausal women, and nulliparity and low parity for both premenopausal and postmenopausal women were significantly associated with an increased risk of breast cancer. The Life Span Study of the Radiation Effects Research Foundation in Hiroshima and Nagasaki showed an inverse association between the number of births and total period of breastfeeding and breast cancer risk [22] . Because the total fertility rate has been gradually decreasing since the 1970s in Japan, this decreased fertility might be one possible explanation for the increased incidence of breast cancer. Furthermore, increasing height, good nutrition, and a Westernized dietary life are all trends observed in Japan during the past two decades. Thus, changing lifestyles might increase breast cancer risk, especially in premenopausal Japanese women. We demonstrated that the frequencies of both ER+/PgR+ and ER+/HER22 tumors were significantly higher in women 50 years or younger than in women over 50 years of age between 2002 and 2010. Moreover, the expression levels of PgR were notably different in the ER-positive, HER2-negative subtype between the two age groups; most tumors showed high PgR expression scores in women 50 years or younger, whereas the distribution of PgR scores was similar in women over 50 years of age. We, and others previously, have reported that expression levels of PgR did not affect response to aromatase inhibitors given as primary endocrine therapy, although expression levels of PgR decreased in posttreatment tumors compared with the levels in pretreatment specimens regardless of the treatment response [23] [24] [25] . In contrast, it was recently identified that expression levels of ER and PgR were predictive for prognosis in postmenopausal patients who were treated with adjuvant endocrine therapy [26, 27] . Our present study demonstrated that expression levels of ER and PgR were strongly and negatively correlated with tumor grade in ERpositive, HER2-negative breast cancer. However, expression levels of neither ER nor PgR were not associated with diseasefree survival in either age group, although tumor grade was significantly correlated with disease-free and overall survival in women 50 years or younger.
Finally, we demonstrated that adjuvant therapies, both endocrine and chemotherapies, have been changed dramatically over the past two decades, and that prognosis in ER-positive, HER2-negative breast cancer has improved over time in both age groups. On the other hand, lymph node status and tumor size were strong prognostic factors regardless of the biological characteristics of the tumors. Recent meta-analysis of outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen indicated that aromatase inhibitors significantly lower recurrence rates compared with tamoxifen [28] . Furthermore, a TransATAC study showed that the risk of distant recurrence was higher for node-positive than node-negative patients and for patients with ‡4 positive nodes than patients with one to three positive nodes, regardless of recurrence scores [29] . It is considered that the characteristics of ER-positive, HER2-negative breast cancer are heterogeneous, and that standard chemotherapy does not improve prognosis for patients with highly endocrine responsive tumors, such as high levels of ER and PgR, low proliferation and low tumor grade [30] . It is necessary to establish new approaches for improving survival for node-positive, ER-positive breast cancer.
In conclusion, the present study indicates that the recent notable increase of Japanese breast cancer incidence is mostly due to an increase in the ER-positive subtype, especially in women aged 50 years or younger. Moreover, prognosis in ERpositive, HER2-negative breast cancer has improved significantly over time due to advances in adjuvant therapies. It is necessary to establish risk factors, both genetic and environmental, capable of predicting the risk of ER-positive breast cancer and thus enable the efficient selection of candidates for hormone receptor-targeted chemoprevention. Furthermore, investigation of risk factors could lead to the identification of the mechanisms concerned in the development of ER-positive breast cancer. 
